t(5;9)(q35;q34) SQSTM1/NUP214
Review on t(5;9)(q35;q34), with data on clinics, and the genes involved.
t(14;16)(q32;q23) IGH/MAF
Review on t(14;16)(q32;q23) IGH/MAF, with data on clinics, and the genes involved.
t(6;8)(p21;q24) MYC/SUPT3H
Review on t(6;8)(p21;q24), with data on clinics, and the genes involved.
Evaluation of a Frequency-Lowering Algorithm for Adults With High-Frequency Hearing Loss.
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The first author was supported by Bernafon AG and received funding from Phonak in the past.
Evaluation of a Frequency-Lowering Algorithm for Adults With High-Frequency Hearing Loss.
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The first author was supported by Bernafon AG and received funding from Phonak in the past.
Evaluation of a Frequency-Lowering Algorithm for Adults With High-Frequency Hearing Loss.
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The first author was supported by Bernafon AG and received funding from Phonak in the past.
Evaluation of a Frequency-Lowering Algorithm for Adults With High-Frequency Hearing Loss.
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The first author was supported by Bernafon AG and received funding from Phonak in the past.
Evaluation of a Frequency-Lowering Algorithm for Adults With High-Frequency Hearing Loss.
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The first author was supported by Bernafon AG and received funding from Phonak in the past.
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survi...
...
National Institute of Health Research (NIHR) Health Technology Assessment Programme (HTA), funding project grant number 06/303/98
Nodal marginal zone lymphoma (NMZL)
Nodal marginal zone lymphoma (NMZL) is a primary nodal B-cell neoplasm that morphlogically resembles lymph nodes involved by MZL of extranodal or splenic types. Two clinicopathological forms of NMZL are recognized: adult type and pediatric-type. NMZLs show overlapping features with other types of MZL, but distinctive features as well. NMZL remains ...
